Medical Oncology

DCIS

Questions discussed in this category

Would you offer adjuvant endocrine therapy to a patient with a history of ER-positive DCIS, s/p bilateral mastectomy, now with chest wall recurrence of DCIS four years later?

Patient in her 30s, initially with intermediate nuclear grade DCIS, ER 100%, 8.4 cm in extent, underwent bilateral mastectomy with widely negative mar...

1 Answer available

How does the potential for a patient to accept or forego adjuvant tamoxifen factor into your recommendations on adjuvant RT for DCIS?

Are there specific patient populations in which you may feel comfortable with a patient selecting only one adjuvant therapy approach (tamoxifen vs RT)...

3 Answers available

Do you utilize Oncotype DX DCIS score to decide on the need and duration of endocrine therapy in patients with DCIS?

1 Answer available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-03-01

RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.

J Clin Oncol, 2021 Aug 18

Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804.

Lancet Oncol, 2010 Dec 07

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-04-20

Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.

Lancet (London, England), 2016-02-27

Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.

Related Topics in Medical Oncology